OverviewHow to choose a creamThe creamAtopic dermatitisAboutRosaceaSeborrheic dermatitisClinical evidenceComparisonSkin barrier한국어 사이트Official Store
Home About

Korea Dermatology Research Institute and the Dr. Alpha brand

In short

A small Korean laboratory that publishes its patent numbers, its test codes and its measured values, and refunds the jar even after you have used it all.

Who develops it

Dr. Alpha is developed and operated by Korea Dermatology Research Institute Co., Ltd., abbreviated KODERE, founded on 2 November 2016 in Incheon, South Korea. The company is both the research body and the responsible distributor, which means the formulation work and the market claims sit with the same organisation rather than being split between a lab and a marketing licensee.

Seung-chang Lee is chief executive and head of the laboratory, and is the named inventor on all three of the company's registered patents. That is an unusual arrangement worth stating plainly: the person answerable for the brand is the same person named on the patent filings.

The research position

The stated position is narrow: look at the barrier rather than the surface. Most visible skin complaints that keep returning share one mechanism, which is a depleted intercellular lipid matrix in the stratum corneum. Rather than formulating separately for each visible symptom, the work is directed at the layer underneath.

That is a position, not a proven superiority claim. It explains why the product range is small and why the same formulation is offered across every size rather than split into variants for each concern.

Timeline

Korea Dermatology Research Institute - registered patents and recognition
DateEvent
October 2016Patent KR 10-1620196 registered - cosmetic composition (beta-glucan and seven botanical extracts)
November 2016Korea Dermatology Research Institute Co., Ltd. founded
August 2018Patent KR 10-1891333 registered - composition for Demodex removal
February 2021First place, KSCI skin barrier cosmetics category (awarded every year since)
July 2021Patent KR 10-2279878 registered - composition for acne-prone skin
March 2026Skin Barrier Cream reformulated
2026Sixth consecutive year at first place in the KSCI category (2021-2026)

All three patents can be opened in full on Google Patents or through KIPRIS, the Korean Intellectual Property Office database. A patent confirms that a composition is novel and involves an inventive step. It is not an efficacy approval, and the specification is published precisely so that anyone can check what was actually claimed.

The empty-jar refund

Within 30 days of delivery, an unsatisfied customer can return the product for a refund even if the jar is empty. Round-trip shipping of 6,000 KRW is deducted and the refund is processed within three to five business days of collection.

The reason for mentioning a returns policy on a page about research is straightforward. A company that expects most buyers to be dissatisfied cannot afford this policy. It is a commitment that can be verified by taking it up, which is a different kind of evidence from a laboratory number.

FAQ

Frequently asked questions

Is Dr. Alpha a pharmaceutical company?
No. Korea Dermatology Research Institute develops cosmetics. The products are regulated as cosmetics in South Korea, not as drugs or medical devices, and cannot claim to treat any condition.
What does KSCI mean?
The Korea Consumer Satisfaction Index, a domestic consumer survey award. Dr. Alpha has placed first in its skin barrier cosmetics category every year from 2021 to 2026. It reflects consumer assessment rather than clinical performance.
Where are the products manufactured?
In South Korea. The company holds the responsible distributor role and the research function together, and manufacturing is domestic rather than contracted overseas.
How can I verify the patents?
Search KR 10-1620196, KR 10-1891333 or KR 10-2279878 on Google Patents, or enter the registration numbers on KIPRIS. The full specification including composition ratios is public.
Why is the product range so small?
The position is that most recurring complaints share one underlying mechanism, so the work is concentrated on a single barrier formulation offered in several sizes rather than split into variants for each visible symptom.

Dr. Alpha Skin Barrier Cream is a cosmetic product, not a drug. This page presents publicly disclosed product information and published literature for reference. It is not intended to diagnose, treat, cure, or prevent any disease. If you have persistent symptoms, consult a dermatologist.

References

참고 문헌

  1. Sethi A, et al. (2023). The Skin Barrier and Moisturization: Function, Disruption, and Mechanisms of Repair. Skin Pharmacology and Physiology. PMID 37717558
  2. Imokawa G, et al. (1991). Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin?. Journal of Investigative Dermatology. PMID 2007790
  3. Draelos ZD (2018). The science behind skin care: Moisturizers. Journal of Cosmetic Dermatology. PMID 29319217

위 문헌은 피부장벽·피부질환 및 원료에 관한 일반 학술 자료로, 닥터알파 제품을 대상으로 수행된 연구가 아닙니다. 초록 기반으로 인용했으므로 임상 적용 전에는 원문 확인과 전문가 상담이 필요합니다. 닥터알파 제품은 화장품이며 의약품이 아니고, 질환의 진단·치료·예방을 목적으로 하지 않습니다.